Zobrazeno 1 - 10
of 2 029
pro vyhledávání: '"second-line therapy"'
Autor:
Ilya V. Savchenko, Ivan S. Stilidi, Irina A. Dzhanyan, Elena Yu. Antonova, Alexander N. Polyakov, Angelina V. Egorova, Svetlana V. Chulkova, Valeriy V. Breder
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 202-209 (2024)
Aim. To evaluate the efficacy and toxicity of second-line polychemotherapy according to FOLFOX or FOLFIRI regimen in patients with biliary tract tumours after progression during first-line chemotherapy (CT). Materials and methods. The study is bas
Externí odkaz:
https://doaj.org/article/6f6ea0a3ddc645fd908b7b946fe00f58
Publikováno v:
Open Medicine, Vol 19, Iss 1, Pp 3829-66 (2024)
Since the outbreak of COVID-19 in December 2019, countries around the world, including China, have been administering COVID-19 vaccines in response to the pandemic. Our center has observed that treating patients with primary immune thrombocytopenia (
Externí odkaz:
https://doaj.org/article/50fdd2363a5f4fc9a0c043be4e7654e7
Publikováno v:
Cancer Medicine, Vol 13, Iss 16, Pp n/a-n/a (2024)
Abstract Objective Few studies have evaluated disparities in race, ethnicity, and health insurance in real‐world health outcomes for patients with diffuse large B‐cell lymphoma (DLBCL). This study aimed to evaluate association between racial disp
Externí odkaz:
https://doaj.org/article/09dcfc6c20f04908be14a5e39c035251
Autor:
Bolun Zhao, Mengyu Zhang, Jingyi Tang, Daopei Zou, Fang Liu, Qiong Shi, Tianwen Gao, Chunying Li, Guannan Zhu
Publikováno v:
Cancer Medicine, Vol 13, Iss 16, Pp n/a-n/a (2024)
Abstract Background Immune‐checkpoint inhibitors are now used more commonly in combination than monotherapy as the first‐line choice in patients with unresectable advanced melanoma. Nevertheless, for cases that progressed after the initial combin
Externí odkaz:
https://doaj.org/article/5e6fc8bb729e431ea4b315924ee220fe
Autor:
Haixia Fu, Xueyan Sun, Ren Lin, Yu Wang, Li Xuan, Han Yao, Yuanyuan Zhang, Xiaodong Mo, Meng lv, Fengmei Zheng, Jun Kong, Fengrong Wang, Chenhua Yan, Tingting Han, Huan Chen, Yao Chen, Feifei Tang, Yuqian Sun, Yuhong Chen, Lanping Xu, Kaiyan Liu, Xi Zhang, Qifa Liu, Xiaojun Huang, Xiaohui Zhang
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background For patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD), effective second-line regimens are urgently needed. Mesenchymal stromal cells (MSCs) have been used as salvage regimens for SR-aGVHD in the past. How
Externí odkaz:
https://doaj.org/article/c450aca802824f03b9e1a77e5f228c85
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 4, Pp 132-139 (2024)
Despite the existing standard treatments for endometrial cancer, the prognosis for these patients remained poor until recently. None of currently available cytostatics ensured long-term disease control and long-term survival of patients receiving sta
Externí odkaz:
https://doaj.org/article/60d0ae2c4915459c9ed72ec7254d4b57
Autor:
T. T. Valiev, A. A. Khachatryan, S. V. Goryacheva, N. A. Batmanova, K. I. Kirgizov, S. R. Varfolomeeva
Publikováno v:
Онкогематология, Vol 19, Iss 1, Pp 40-50 (2024)
The use of high-effective, multicomponent, risk-adopted chemoimmunotherapy schemes in children with Burkitt lymphoma reached advanced long-term progression-free survival over 90 % even for high risk patients. Unfortunately, conventional therapeutic s
Externí odkaz:
https://doaj.org/article/3c78d79e364b4d8d9aebc4aac47983aa
Autor:
Yutaka Takahara, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa
Publikováno v:
Thoracic Cancer, Vol 14, Iss 36, Pp 3549-3555 (2023)
Abstract Background Several options for second‐line therapy are available for patients with advanced non‐small cell lung cancer (NSCLC); however, the optimal therapy remains unclear. Docetaxel (DTX) monotherapy and DTX plus ramucirumab (RAM) are
Externí odkaz:
https://doaj.org/article/3dfcc8af26d449629347ab88334f53e4
Autor:
Liang Qiao, Wei He, Guoying Wang, Huanwei Chen, Fuxi Huang, Bo Zhang, Yuxiong Qiu, Shaoru Liu, Zhenkun Huang, Yichuan Yuan, Jiliang Qiu, Yunfei Yuan, Binkui Li
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Introduction Regorafenib remains the standard and widely used second‐line strategy for advanced hepatocellular carcinoma (HCC). There is still a lack of large‐scale multicenter real‐world evidence concerning the concurrent use of regor
Externí odkaz:
https://doaj.org/article/d7b100f5750b4f9486922d99dd9bd705
Autor:
S. K. Zyryanov, I. N. Dyakov
Publikováno v:
Фармакоэкономика, Vol 16, Iss 3, Pp 422-430 (2023)
Objective: to evaluate the pharmacoeconomic efficiency of atezolizumab (inhibitor of programmed death ligand 1 (PD-L1)) in comparison with other checkpoint inhibitors (inhibitors of programmed cell death protein 1 (PD-1)) in patients with advanced no
Externí odkaz:
https://doaj.org/article/5656c1d6fa50463293e6ecaf843b805f